Glaxosmithkline Pharmaceuticals' Q1 FY 2025-26 Quarterly Results

Result Summary

• Glaxosmithkline Pharmaceuticals Ltd reported a 11.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.2%.
• Its expenses for the quarter were down by 17.6% QoQ and 5.2% YoY.
• The net profit increased 5.4% QoQ and increased 12.4% YoY.
• The earnings per share (EPS) of Glaxosmithkline Pharmaceuticals Ltd stood at 12.1 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glaxosmithkline Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, primarily engaged in the production and distribution of medicines and vaccines. The company is known for its innovative healthcare solutions and has a strong presence in the Indian pharmaceutical market. Its portfolio includes a wide range of products catering to various therapeutic areas, including respiratory, anti-infectives, vaccines, dermatology, and oncology. As of the latest update, there is no specific information on recent major developments for Glaxosmithkline Pharmaceuticals Ltd. However, the company is generally active in research and development, consistently striving to introduce new and effective medical treatments.

Revenue

For the first quarter of the fiscal year 2026, Glaxosmithkline Pharmaceuticals Ltd reported a total income of ₹848.89 crores. This represents a decline of 11.5% compared to the previous quarter (Q4FY25), where the total income was ₹959.63 crores. On a year-over-year basis, the revenue has seen a marginal decrease of 0.2% from ₹850.29 crores in Q1FY25. Despite these declines, the company has managed to maintain its income levels relatively close to those of the same quarter last year, indicating stability in its revenue streams.

Profitability

In terms of profitability, Glaxosmithkline Pharmaceuticals Ltd achieved a Profit Before Tax (PBT) of ₹278.98 crores in Q1FY26, which marks an increase of 3.1% from ₹270.62 crores in Q4FY25. Compared to the same quarter in the previous year, the PBT has grown by 11.9% from ₹249.40 crores. The Profit After Tax (PAT) for the current quarter stands at ₹205.01 crores, reflecting a 5.4% quarter-over-quarter increase and a 12.4% rise year-over-year. This growth in profitability is further underscored by an increase in Earnings Per Share (EPS), which rose to ₹12.10 in Q1FY26 from ₹11.50 in Q4FY25 and ₹10.80 in Q1FY25. These figures suggest an upward trajectory in the company's profitability metrics.

Operating Metrics

The company has effectively managed its expenses, with total expenses reported at ₹569.91 crores for Q1FY26, a significant reduction of 17.6% from ₹691.41 crores in the previous quarter. When compared to the same quarter last year, total expenses decreased by 5.2% from ₹600.89 crores. This efficient cost management has contributed to the improved profitability metrics despite the decrease in total income. The tax expense for the quarter was ₹73.97 crores, slightly lower than the previous quarter's ₹76.14 crores but higher than ₹67.07 crores in Q1FY25, reflecting a modest year-over-year increase. Overall, the financial data for Q1FY26 highlights effective operational management in terms of expense control and tax optimization.